Pfizer prevails in Sutent patent dispute

23 October 2014
drugs_pills_tablets_big

The US District Court for the District of Delaware has upheld US pharma giant Pfizer’s (NYSE: PFE) basic patent and the L-malate salt patent covering Sutent (sunitinib malate) capsules.

This decision, which is subject to appeal, affirms Pfizer’s right to exclusively provide sunitinib malate as Sutent to patients through the term of the patent, which expires in 2021. Sutent, a treatment for advanced kidney cancer, gastrointestinal and pancreatic tumors, generated sales of about $578 million in the first half of this year.

“The Court’s decision acknowledges the validity and infringement of our patents and affirms the value of Sutent, standard of care in the treatment of advanced renal cell carcinoma,” said Douglas Lankler, executive vice president and general counsel for Pfizer. “Defending our intellectual property is crucial to our ability to discover and develop innovative new medicines, which is at the very core of what we do,” he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics